Factors to Consider When Switching Therapies

Author(s):

Kirollos Hanna, PharmD, BCPS, BCOP,Brandon Dyson, PharmD, BCPS

The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.

EP: 1.BTK Inhibitor-Associated Adverse Events

EP: 2.Managing Adverse Events and Supportive Care Measures in CLL Treatment

EP: 3.Impact of Dose Modifications on CLL Treatment

EP: 4.Considerations for Dose Modifications

EP: 5.Economic Impact of Dose Modifications on CLL Management

Now Viewing

EP: 6.Factors to Consider When Switching Therapies

EP: 7.Medicare Part D Smoothing Program: Impact on Access and Adherence

Video content above is prompted by the following:

When is transitioning to a new therapeutic option considered, and what factors influence the decision between dose modification and switching therapies in chronic lymphocytic leukemia treatment?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!